In this study, we establish an experimental platform to simultaneously measure: a) genetically encoded calcium indicators (GCaMP) expressing on the excitatory neurons using fiber-photometry, b) cerebral blood volume (CBV) using fiber-photometry, and c) CBV using fMRI. By this platform, we assess neurovascular coupling (GCaMP and CBV comparisons) under chemogenetic stimulation of S1 excitatory neurons in a group of freely moving rats, and demonstrate this platform for concurrent GCaMP, photometry-CBV, and fMRI-CBV measurements with chemogenetic manipulation.
INTRODUCTION
Chemogenetics, a.k.a. Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) utilizes engineered muscarinic or opioid receptors that remain silent until triggered by otherwise inert synthetic ligands.1 Pertinent to the unique strength of DREADDs for remote control of selected cellular activity, its combination with fMRI and optical measures has enabled a highly multiplexed platform for studying neurovascular coupling across spatiotemporal scales. In this study, we first establish an experimental platform to simultaneously measure 3 neurophysiological parameters, namely, a) genetically encoded calcium indicators (GCaMP) expressing on the excitatory neurons using fiber-photometry, b) cerebral blood volume (CBV) using fiber-photometry, and c) CBV using fMRI. Next, we compare two independent CBV measures (photometry versus fMRI) under somatosensory forepaw stimulation and optogenetic stimulation of the cortical (S1) excitatory neurons. We then apply this platform to assess neurovascular coupling (GCaMP and CBV comparisons) under chemogenetic stimulation of S1 excitatory neurons in a group of freely moving rats. Lastly, we demonstrate this platform for concurrent GCaMP, photometry-CBV, and fMRI-CBV measurements with chemogenetic manipulation.RESULTS & DISCUSSION
Both forepaw and optical stimulations evoked similar spatial activation (Figure 2A&B). Photometry-CBV showed more than 3-fold higher contrast-to-noise-ratio (CNR) when comparing with fMRI-CBV (Figure 2C-F&H-J). The response time-courses of both CBV measures exhibited high linear correlation (r=0.82 and 0.71 for forepaw and optogenetic stimulation, respectively (Figure 2 G&I). CNO administration at 5mg/kg, but not 1mg/kg, induced long-lasting increase of both photometry-CBV and GCaMP6f group-averaged responses (Figure 3A&C). We found that the SNR of photometry-CBV decreased with time at a time constant of ~166 min, likely due to Rhodamine B wash-out, whereas the SNR of GCaMP6f remains stable over-time (Figure 3B&D). We also show data from a representative subject in Figure 3E&F, and found that neurovascular coupling plot of CBV versus GCaMP6f depicted two distinct clusters, recapitulating responses before and after CNO administration (Figure 3G). We have also shown that the Rhodamine time-course is highly predictable by convolving GCaMP6f time-course with a transferred hemodynamic response function (HRF) (Figure 3H&I). Figure 4A shows confocal images of a representative subject with robust co-expression of Gq-DREADD and GCaMP6f in S1 neurons. Concurrent fMRI and Rhodamine/GCaMP fiber-photometry recordings (Figure 4B-D) show significant correlation between two independent CBV measurement using fMRI and photometry (r=.76, Figure 4E). We have also demonstrated the coupling coefficient between GCaMP6f and Rhodamine B measures (r=.47, Figure 4F). We expect this platform to be an attractive means to identify the contributions of select circuits and cell populations to hemodynamic signals during macroscopic fMRI measures, and serve as a useful steppingstone towards a more profound understanding of fMRI signaling mechanisms.